Comparing eptinezumab with onabotulinumtoxinA in the treatment of chronic migraine: a real-world evidence study
Abstract Background Migraine, a spectrum of episodic headache disorders common in the global population, may evolve into a very debilitating chronic condition, usually underdiagnosed, poorly recognized and difficult to manage. Neurotransmission in the trigeminovascular sensory nervous system, partic...
Saved in:
| Main Authors: | Damiana Scuteri, Martina Pagliaro, Rosario Iannacchero, Michele Trimboli, Gary W. Lawrence, Giacinto Bagetta, Maria Tiziana Corasaniti |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | The Journal of Headache and Pain |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s10194-025-02106-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comprehensive safety analysis of adverse events associated with eptinezumab in migraine treatment
by: Junchen Chen, et al.
Published: (2025-07-01) -
Impact of eptinezumab on work productivity beyond reductions in monthly migraine days: post hoc analysis of the DELIVER trial
by: Piero Barbanti, et al.
Published: (2024-12-01) -
Efficacy of onabotulinumtoxinA treatment in episodic migraine
by: Jasem Al-Hashel, et al.
Published: (2025-01-01) -
Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab)
by: Davor Jančuljak, et al.
Published: (2024-01-01) -
Translational Impact of Genetics and Epigenetics of CGRP System on Chronic Migraine Treatment with Onabotulinumtoxin A and Other Biotech Drugs
by: Damiana Scuteri, et al.
Published: (2025-07-01)